Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.57 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.57 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869622 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12449187 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL27209163 | 0.84 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13050999 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL1008896 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL4408215 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL4697419 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL29160811 | 0.79 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL20120011 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL15258056 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | CHRNB2 3419/4885CHRNA4 2617/4885CHRNA3 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.